Monday 23 December 2024

The Pharma Letter Podcast — Episode 12 — Mastering the microbiome

Biotechnology
Simon Wentworth
9 March 2022
episode12-b

More on this story...

Biotechnology
New show of faith in microbiome with EnteroBiotix financing
7 September 2021
Biotechnology
Seres Therapeutics falls despite positive Phase III results with SER-109
24 May 2022
Pharmaceutical
Former Merck KGaA heavyweight joins EnteroBiotix as executive chairman
17 July 2023
Biotechnology
MaaT Pharma partners with Skyepharma on microbiome production
9 February 2022


Companies featured in this story

More ones to watch >


Today's issue

FDA priority review for Nuvation Bio's taletrectinib
Pharmaceutical
FDA priority review for Nuvation Bio's taletrectinib
23 December 2024
Pharmaceutical
Grifols’ Albutein misses primary Phase III endpoint
23 December 2024
Pharmaceutical
Denmark sets price ceiling for hospital meds
23 December 2024
Generics
FTC orders Teva to delist inhaler patents
23 December 2024
Pharmaceutical
Sanofi expands SK bioscience deal for pneumococcal conjugate vaccines
23 December 2024
Pharmaceutical
Vertex nabs FDA approval for Alyftrek and Trikafta
23 December 2024
Pharmaceutical
FDA nod for Rhythm Pharma’s Imcivree
23 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

FDA approves Novo Nordisk’s Alhemo
22 December 2024
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze